The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis

Glioblastoma (GBM), an invasive solid tumor, is the most common primary tumor of the brain [1,2]. The standard treatment is radiotherapy (RT) plus concomitant and adjuvant therapy, with six cycles of temozolomide (TMZ) following surgical removal of the maximum safe scope, which is currently the internationally accepted treatment protocol (also was the Stupp protocol). However, despite the availability of advanced treatment, patients with GBM have a poor prognosis, with average survival of only 14.6 –16 months and a 5-year survival rate of less than 10%, thus representing a significant treatment challenge [3–5].
Source: Clinical Neurology and Neurosurgery - Category: Neurosurgery Authors: Source Type: research